Glomerulonephritis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 11: | Line 11: | ||
! rowspan="2" |Causes and associations | ! rowspan="2" |Causes and associations | ||
! colspan="7" |History and symtoms | ! colspan="7" |History and symtoms | ||
! rowspan="2" |Hyperlipidemia and hypercholesterolemia | |||
! rowspan="2" |Nephrotic features | ! rowspan="2" |Nephrotic features | ||
! rowspan="2" |Nephritic features | ! rowspan="2" |Nephritic features | ||
Line 39: | Line 40: | ||
* Hodgkin lymphoma | * Hodgkin lymphoma | ||
* Thrombosis (due to urinary loss of antithrombin-III) | * Thrombosis (due to urinary loss of antithrombin-III) | ||
!+ | |||
!- | |||
! | !- | ||
! | !- | ||
! | !+/- | ||
! | !- | ||
! | !+ | ||
! | |||
!+ | !+ | ||
!- | !- | ||
Line 54: | Line 54: | ||
! | ! | ||
* Normal | * Normal | ||
!Fusion of podocytes | ! | ||
* Fusion of podocytes | |||
!- | !- | ||
|- | |- | ||
Line 68: | Line 69: | ||
| | | | ||
* Adults | * Adults | ||
|<nowiki>+</nowiki> | |||
|<nowiki>-</nowiki> | |||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | | + | ||
| | |||
| + | | + | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 95: | Line 95: | ||
* Drugs (NSAIDS, penclliamine, gold, captopril) | * Drugs (NSAIDS, penclliamine, gold, captopril) | ||
| | | | ||
|<nowiki>+</nowiki> | |||
|<nowiki>-</nowiki> | |||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>-</nowiki> | ||
| | | + | ||
| | |||
| + | | + | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 123: | Line 122: | ||
* History of mucosal infections (e.g. gastroenteritis) and upper respiratory tract infection | * History of mucosal infections (e.g. gastroenteritis) and upper respiratory tract infection | ||
* 2-3 days after infection (synpharyngitic) | * 2-3 days after infection (synpharyngitic) | ||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | |<nowiki>-</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+/-</nowiki> | ||
| | | - | ||
| | |||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 153: | Line 150: | ||
* Periorbital edema | * Periorbital edema | ||
* Hypertension | * Hypertension | ||
| | |<nowiki>+/-</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| - | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | | | ||
* Hypercellular and inflamed glomeruli (Crescent formation) | |||
| | | | ||
|<nowiki>+ (Linear)</nowiki> | |<nowiki>+ (Linear)</nowiki> | ||
Line 171: | Line 170: | ||
* Post infectious glomerulonephritis | * Post infectious glomerulonephritis | ||
| | | | ||
* Streptococcal skin infections | * Streptococcal skin infections | ||
* Streptococcal pharyngitis | * Streptococcal pharyngitis | ||
* 2-3 weeks after infection | * 2-3 weeks after infection | ||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+</nowiki> | |||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |<nowiki>+</nowiki> | ||
| | |||
| | |||
| | | | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 209: | Line 204: | ||
* Hypertension | * Hypertension | ||
* Peripheral neuropathy | * Peripheral neuropathy | ||
| | |||
| | | | ||
| | | | ||
Line 221: | Line 217: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
* Crescent formation | * Hypercellular and inflamed glomeruli (Crescent formation) | ||
| | | | ||
* Sub-epithelial immune complex deposits | * Sub-epithelial immune complex deposits | ||
Line 237: | Line 233: | ||
* Hypertension | * Hypertension | ||
* Peripheral neuropathy | * Peripheral neuropathy | ||
| | |||
| | | | ||
| | | | ||
Line 250: | Line 247: | ||
| | | | ||
| | | | ||
* Hypercellular and inflamed glomeruli (Crescent formation) | |||
| | | | ||
| | | | ||
Line 262: | Line 260: | ||
* Periorbital edema | * Periorbital edema | ||
* Hypertension | * Hypertension | ||
| | |||
| | | | ||
| | | | ||
Line 275: | Line 274: | ||
| | | | ||
| | | | ||
* Hypercellular and inflamed glomeruli (Crescent formation) | |||
| | | | ||
| | | | ||
Line 288: | Line 288: | ||
* Periorbital edema | * Periorbital edema | ||
* Hypertension | * Hypertension | ||
| | |||
| | | | ||
| | | |
Revision as of 14:23, 11 April 2018
Glomerulonephritis Main page |
|
---|
Overview
Differential Diagnosis
Glomerulonephritis | Sub-entity | Causes and associations | History and symtoms | Hyperlipidemia and hypercholesterolemia | Nephrotic features | Nephritic features | ANCA | Anti-glomerular basement membrane antibody (Anti-GBM antibody) | Immune complex formation | Light microscope | Electron microscope | Immunoflourescence pattern | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
History | Pitting edema | Hemeturia (Gross or microscopic) | Hypertension | Hemoptysis | Oliguria | Peri-orbital edema | ||||||||||||
Non-proliferative | Minimal change disease |
|
|
+ | - | - | - | +/- | - | + | + | - | - | - | - |
|
|
- |
Focal segmental glomerulosclerosis |
|
|
+ | - | - | - | +/- | - | + | + | - | - | - | - |
|
|
||
Membranous glomerulonephritis |
|
+ | - | - | - | +/- | - | + | + | - | - | - | + |
|
|
|||
Proliferative | IgA nephropathy |
|
|
+/- | + | + | - | + | +/- | - | - | + | - | - | + |
|
|
|
Rapidly progressive glomerulonephritis |
|
|
+/- | + | + | + | + | + | - | - | + | - | + | + |
|
+ (Linear) | ||
|
|
+/- | + | + | + | + | + | - | + | - | - | + |
|
|
+ (granular) | |||
|
|
- | + | + (C-ANCA) | - | - |
|
|
||||||||||
|
|
- | + |
+ (C-ANCA) |
- |
|
||||||||||||
|
|
- | + |
+ (P-ANCA) |
- |
|
||||||||||||
Membranoproliferative glomerulonephritis |
|
|
+ | - | - | - |